Human BST2/Tetherin Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: BST-2/Tetherin

BST2, also known as Tetherin or PDCA1 and designated CD317, is a 30-35 kDa interferon-inducible protein that associates with the plasma membrane with its transmembrane segment and GPI anchor. BST2 is expressed on bone marrow stromal cells and is upregulated in breast cancer and astrocytoma. It binds to ILT7 on plasmacytoid dendritic cells and inhibits proinflammatory TLR7 and TLR9 signaling. BST2 inhibits the release of Kaposi sarcoma virus, HIV-1, and Lassa virus from infected cells, but this function is counteracted by viral proteins which directly bind and trigger the degradation of BST2. Human BST2 is synthesized with a 20 aa cytoplasmic domain, a 28 aa transmembrane segment, a 113 aa extracellular domain, and a 19 aa C-terminal propeptide. Following removal of the propeptide BST2 is modified with a GPI anchor at Ser161. Within the peptide immunogen which represents aa 103-117 of the ECD, human BST2 shares 28% aa sequence identity with mouse and rat BST2.

Product Datasheets

Related Research Areas

• Dendritic Cell Activation
• Infectious Diseases
• Plasmacytoid Dendritic Cells
• T Cell Antigen Recognition